← Leaderboards
John Didsbury
T3d Therapeutics, Inc.
$25,404,421
Attributed
$26,361,868
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.1M · FY2015–25$10M$7.5M$5M$2.5M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,361,868 · 4
By mechanism
R01$20,365,584 · 1
R44$5,996,284 · 3
Top collaborators
- Suzanne M. De La Monte3 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseResearch Clinical TestingDoseNuclear ReceptorsSmall MoleculeCd3d GeneAgonistDesignPharmaceutical PreparationsCognitionInvestigational DrugsSignal TransductionSeveritiesGlucose MetabolismPlacebosDouble-Blind MethodClinical TrialsOralRandomizedLipid MetabolismBrain DysfunctionEnergy MetabolismBrain
Grant awards (14)
Clinical Development Enablement â Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimerâs Disease Drug Candidate T3D-959$203,807
R44 · FY2025 · AG · contact PI
Clinical Development Enablement â Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimerâs Disease Drug Candidate T3D-959$1,009,699
R44 · FY2024 · AG · contact PI
Clinical Development Enablement â Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimerâs Disease Drug Candidate T3D-959$1,249,334
R44 · FY2023 · AG · contact PI
Phase 2 Enabling Studies of a Candidate Drug Therapy (T3D-959) Regulating Neurometabolism for the Treatment of Huntington's Disease$529,782
R44 · FY2023 · NS · contact PI
Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects$5,526,538
R01 · FY2022 · AG · contact PI
Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects$1,520,269
R01 · FY2022 · AG · contact PI
Phase 2 Enabling Studies of a Candidate Drug Therapy (T3D-959) Regulating Neurometabolism for the Treatment of Huntington's Disease$1,088,768
R44 · FY2022 · NS · contact PI
Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects$5,526,539
R01 · FY2021 · AG · contact PI
Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects$3,102,477
R01 · FY2020 · AG · contact PI
Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects$2,396,962
R01 · FY2020 · AG · contact PI
Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of T3D-959 in Mild to Moderate Alzheimer's Disease Subjects$2,292,799
R01 · FY2019 · AG · contact PI
Clinical Evaluation of T3D-959 as a Potential Disease Remedial Therapeutic for the Treatment of Alzheimer's Disease$686,939
R44 · FY2016 · AG · contact PI
Clinical Evaluation of T3D-959 as a Potential Disease Remedial Therapeutic for the Treatment of Alzheimer's Disease$100,000
R44 · FY2016 · AG · contact PI
Clinical Evaluation of T3D-959 as a Potential Disease Remedial Therapeutic for the Treatment of Alzheimer's Disease$1,127,955
R44 · FY2015 · AG · contact PI